Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing

Viking Therapeutics, Inc.

2022-Q3 EPS reported -$0.55

Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.
Cash, cash equivalents and short-term investments of $216.1M as of Sept 30, 2021 ($248.4M at Dec 31, 2020).
Phase 2b VOYAGE trial for VK2809 (NASH) enrolling; initial data expected in 2022.
Phase 1b trial of VK0214 in X-ALD (AMN) underway; top-line results expected in 2022.
Preclinical dual GLP-1/GIP agonists showed up to 27% body weight reduction; clinical development planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.